Abstract
This study explores the potential of non-neural progenitor cells for CNS cell therapy. Muscle progenitor cells (MPCs), transplanted either intraventricularly or intraperitonealy, incorporated into the CNS of EAE-induced but not of naïve mice. Some of the migrating MPCs expressed the neuronal marker beta-III-Tubulin and gained neuronal morphology. Co-treatment of transplanted mice with the immunomodulatory agent glatiramer acetate (GA, Copaxone) resulted in improved MPCs incorporation and differentiation towards the neuronal pathway. The therapeutic potential of myogenic progenitor cells was demonstrated by amelioration of clinical symptoms and reduced mortality in EAE mice, as well as by expression of IL-10, TGF-beta, and the neurotrophin-BDNF.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biomarkers / metabolism
-
Cell Movement / drug effects
-
Cell Movement / immunology
-
Cells, Cultured
-
Central Nervous System / cytology
-
Central Nervous System / immunology*
-
Encephalomyelitis, Autoimmune, Experimental / immunology*
-
Encephalomyelitis, Autoimmune, Experimental / metabolism
-
Encephalomyelitis, Autoimmune, Experimental / pathology
-
Encephalomyelitis, Autoimmune, Experimental / therapy*
-
Female
-
Glatiramer Acetate
-
Humans
-
Mesenchymal Stem Cell Transplantation*
-
Mice
-
Mice, Inbred C57BL
-
Mice, Transgenic
-
Myoblasts, Skeletal / drug effects
-
Myoblasts, Skeletal / immunology*
-
Myoblasts, Skeletal / transplantation*
-
Peptides / administration & dosage
-
Rats
-
Stem Cells / cytology
-
Stem Cells / drug effects
-
Stem Cells / immunology
Substances
-
Biomarkers
-
Peptides
-
Glatiramer Acetate